Hepatitis B vaccines in patients with chronic renal failure before dialysis.

Journal Article (Clinical Trial;Journal Article)

Hepatitis B remains a significant risk to patients receiving chronic hemodialysis, but no certain method of prevention has been identified. We tested two vaccines, plasma-derived vaccine (40-micrograms dose) and recombinant-derived vaccine (40-micrograms and 20-micrograms doses), in 61 patients with chronic renal failure who were not yet dependent on dialysis. Patients were followed up clinically and with laboratory tests of kidney function and hepatitis B virus serology for one year. Significantly more recipients of plasma-derived vaccine responded to vaccination; they also achieved a higher titer of antibody to hepatitis B virus than did recipients of recombinant-derived vaccine when evaluated at 6, 7, 9, and 12 mo after vaccination. No serious side effects were observed with any vaccine preparation, nor were excessive adverse effects observed in any group. Compared with the dialysis patients previously studied, patients with renal failure who were not yet dependent on dialysis responded more favorably to the hepatitis B virus vaccine.

Full Text

Duke Authors

Cited Authors

  • Seaworth, B; Drucker, J; Starling, J; Drucker, R; Stevens, C; Hamilton, J

Published Date

  • February 1, 1988

Published In

Volume / Issue

  • 157 / 2

Start / End Page

  • 332 - 337

PubMed ID

  • 2961818

International Standard Serial Number (ISSN)

  • 0022-1899

Digital Object Identifier (DOI)

  • 10.1093/infdis/157.2.332


  • eng

Conference Location

  • United States